A major breakthrough in brain health
Now coming to Everlab.
pTau‑217 is a new blood test that helps clinicians understand one of the strongest biological signals associated with Alzheimer’s disease. Everlab is the first preventative healthcare service in Australia to offer it to eligible members.
.avif)
Dr Steven Lu, Chief Medical Officer, on what pTau-217 means for our members.
Why pTau-217 matters
For decades, understanding whether someone may be developing Alzheimer's disease has often relied on specialised brain imaging or invasive procedures. pTau-217 represents a significant step forward, giving clinicians a simpler way to understand one of the strongest biological signals associated with Alzheimer's disease using a blood test.
While no single test can diagnose Alzheimer's disease on its own, pTau-217 adds an important new tool to help clinicians build a clearer picture of brain health.
Why Everlab
is offering it
Everlab exists to bring clinically meaningful advances in preventative medicine to our members as early as possible. That's why we're proud to be the first preventative healthcare service in Australia to offer pTau-217 to eligible members.
We continually evaluate emerging diagnostics with strong clinical evidence, making important advances available when they can meaningfully improve care.
Want to be among the first to know when it arrives?
Leave your email and we’ll let you know the moment pTau‑217 becomes available to eligible members.